Objective: Here we report our experience of patients with squamous cell carcinoma (SCC) of the nasal cavity and ethmoid sinus (NC&ES) together with an analysis of treatment outcomes.
Malignant tumors of the nasal cavity and ethmoid sinus (NC&ES) are rare neoplasms that constitute approximately 35% of all malignancies of the paranasal sinuses and nasal cavity in Japan [1] , although lower rates are reported in Western countries. NC&ES fall into the same category of anatomic site and their stages are determined using the same criteria in the UICC classification.
The number of patients with malignant tumors of NC&ES treated at a single center is small. Therefore, some reports have included patients from several decades ago, and the time factor must have influence on pretreatment diagnosis and treatment outcome. Indeed, the application of endonasal endoscopic resection of NC&ES tumors has been increasing, and induction chemotherapy and concomitant chemoradiotherapy have been developed for head and neck cancers in recent times. In addition, there are many histological types of malignant tumors that develop in the paranasal sinuses and nasal cavity, such as squamous cell carcinoma (SCC), adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, olfactory neuroblastoma, malignant melanoma, undifferentiated carcinoma, and so on. Therefore, there is a scarcity of prospectively collected data on the management options and outcomes because of the rarity of this disease [2] . The retrospective data collected to date also include data for different sites, such as the maxillary sinus, which accounts for over 50% of sinonasal malignancies, as well as data for many histological types. Therefore, it is difficult to know how to treat patients with tumors in a specific site and with a specific histology. In this study, we focused on SCC of the NC&ES, which is one of the major histological types of NC&ES.
The purpose of the present study was to report our experience with 25 consecutive patients with SCC of the NC&ES after 2000, with an analysis of treatment outcomes.
MATERIALS AND METHODS
A retrospective analysis was performed on data from 25 consecutive patients with previously untreated SCC of NC&ES treated between January 2000 and December 2012 in Hokkaido University Hospital. One patient was excluded because he was treated with palliative intent due to his poor medical condition.
All patients were initially evaluated by a multidisciplinary team consisting of head and neck surgeons and radiation oncologists, and tumors were classified according to the 7 th Edition of the Union for International Cancer Control (UICC) staging system published in 2009. Patients visiting our hospital before 2009 were restaged according to the UICC 7 th edition. The stage of the tumor was determined on the basis of patient history, physical examination, chest x-rays, as well as computed tomography (CT) and/or magnetic resonance imaging (MRI). Approval for this study was obtained from the Institutional Review Board at Hokkaido University.
Treatment strategies
All cases were discussed by a multidisciplinary tumor board. All 25 patients were treated with curative intent. In accord with our institutional policy, limited disease (T1-2 N0) was treated by surgery or radiotherapy alone. Radiotherapy was recommended if adverse features, such as positive or close margins, were confirmed pathologically. Locally advanced and resectable disease was treated by a combination of surgery followed by adjuvant radiotherapy or radiotherapy with intravenous (IV) or intra-arterial (IA) chemotherapy, and unresectable tumors were treated by radiotherapy with chemotherapy (IV or IA).
Statistical analysis
All patients were closely observed during the follow-up period, with the median follow-up period for surviving patients ranging from 1.5 to 14 years (median, 8.3 years).
In this study, the detailed anatomical sites in which the primary tumor developed were evaluated using CT and MR imaging. The primary tumor extension sites were classified according to the 7 th UICC staging system and included the medial wall or floor of the orbit, maxillary sinus, palate, cribriform plate, anterior orbital contents, skin of the nose or cheek, minimal extension to the anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses, orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, and clivus.
The probability of overall survival was computed from the beginning of treatment to the time of death from any cause or the date of the last follow-up contact for surviving patients, and the probability of disease-specific survival was computed to death from disease or the date of last follow-up contact for surviving patients. They were calculated by the Kaplan-Meier method and compared using the log-rank test. Two-sided P values <0.05 were considered statistically significant. A prognostic analysis was performed to study the following variables: age, sex, and extension to the primary tumor extension sites. Statistical analysis was performed using JMP Pro 11.0.0 statistical software (SAS Institute, Cary, NC).
RESULTS

Patient Characteristics
Twenty-five patients were enrolled in this study. Patients consisted of 17 males and 8 females, with a median age of 65 years (range 25-81 years). Thirteen patients (52%) had tumors arising in the ethmoid sinus, and 12 (48%) in the nasal cavity. Four patients (16%) was diagnosed with T1, 3 (12%) with T2, 4 (16%) with T3, 7 (28%) with T4a, and 7 (28%) with T4b disease. No lymph node involvement was noted in any patients (Table 1) .
Inverted papillomas were found in surgical or biopsy specimens from 4 patients.
Treatment modalities
Treatment according to T stage is shown in Table 2 . Twelve patients (48%) were treated with surgery. Of these, 4 (16%) were treated with surgery alone, 6 (24%) with surgery and postoperative radiotherapy, and 2 (8%) with induction chemotherapy, surgery, and postoperative radiotherapy. Thirteen patients (52%) underwent radiotherapy without surgery. Of these, one patient (4%) was treated with radiotherapy alone. Radiotherapy and concomitant intravenous chemotherapy (IV-CRT) were undertaken for 4 (16%), and 2 (8%) patients also received induction chemotherapy. Eight patients (32%) were treated with radiotherapy and concomitant intra-arterial chemotherapy (RADPLAT). The treatment protocol for IV-CRT and RADPLAT has been described elsewhere [3] [4] [5] [6] . To summarize, Surgical approach according to T stage is shown in Table 3 . Of the 12 patients who underwent surgery, 4 patients received endonasal endoscopic surgery without an open approach. A further two patients underwent tumor resection via a nasal-alar sulcus incision and endoscopic endoscopy to achieve a good view of the tumor and allow resection with an adequate margin as the tumors were located tangential to the external nares. One patient underwent tumor resection by a gingivobuccal approach with endoscopy. Two patients also underwent resection via lateral rhinotomy. All 9 of these patients presented with limited disease (T1-3) of the NC&ES. The remaining 3 patients with T4 disease were treated via an anterior skull base approach with an endonasal endoscopic approach and with/without a lateral rhinotomy approach. Reconstruction of the surgical defect of the anterior skull base using a pericranial flap was required in all 3 patients. The remaining 9 patients did not need reconstruction, and the postoperative course was uneventful in all 9 patients.
Overall Survival and Disease-specific Survival Rates
The 5-year overall survival and disease-specific survival rate calculated by the Kaplan-Meier method, was 52.3% and 59.9%, respectively ( Figure 1 ). Seven patients died of primary site recurrence and 2 patients of distant metastasis without primary site recurrence. Two patients with T2 tumor died of other causes. The 5-yr overall survival for T1-3, T4a, and T4b disease was 53.9%, 71.4%, and 29.0%, respectively. The 5-yr disease-specific survival for T1-3, T4a, and T4b disease was 74.1%, 71.4%, and 29.0%, respectively ( Figure 2 ). Patients with T4b had a worse disease-specific survival rate than did those with T1-3 (p=0.0413).
Univariate Cox proportional hazards analysis revealed that the medial wall or floor of the orbit extension, pterygoid plate extension, and orbital apex extension were factors for OS (Table 4 ). However, they were not found to be independent factors for OS in the multivariate analysis. Age, sex, and extension to other anatomical sites were not factors for OS in the univariate analysis.
DISCUSSION
SCC is aggressive cancer, so surgery, by means of en bloc resection, was traditionally regarded as the ideal form of intervention. However, transoral resection has been becoming more popular for head and neck cancer, especially for oropharyngeal and laryngeal caner. Hinni et al. concluded that piecemeal removal of tumors with three-dimensional margin mapping using an operating microscope or rod telescope is safe from an oncologic standpoint, and reduces morbidity and length of hospital stay [7, 8] .
As for cancer of the NC&ES, en bloc resection is not often achieved even by lateral rhinotomy and/or an anterior skull base approach, and usually requires debulking or CRT has received little attention with regard to the treatment of sininasal cancer [10] .
In this study, CRT without NAC was applied in 2 patients, but failed. NAC followed by CRT was also performed for 2 patients, one of whom remains alive without disease to date.
Hanna et al. reported that NAC is a promising technique that may improve treatment outcomes for patients with SCC of the paranasal sinuses [11] , and NAC followed by CRT is also considered to be an option for locally advanced NC&ES.
We previously reported the efficacy of RADPLAT for the treatment of tumors in the nasal cavity and the paranasal sinus [3] . However, we did not focus on SCC of the NC&ES in that study. As we previously reported, RADPLAT is considered to be effective for the treatment of patients with locally advanced SCC of the nasal vestibule, with excellent cosmetic results reported [5] . As for NC&ES, tumors are expected to be mainly supplied by the external carotid system, but also partially supplied by the internal carotid system, such as the anterior and posterior ethmoid arteries, particularly when the tumors arise from ethmoid sinus. However, the external carotid system provided the main supply to the tumor in most cases. We have infused cisplatin into the external carotid system, but not into the internal carotid system to avoid CNS and optic complications (Figure 3) . As a result, cisplatin was infused from the internal maxillary artery in all 8 patients, the facial artery in 3 patients, and the transverse facial artery in 2 patients. In the remaining patient with T4a ethmoid cancer, angiography revealed that the tumor was not supplied by the external carotid system at all. Therefore, RADPLAT was not indicated in this case, and the patient received IV-CRT. Acute toxicity (≥grade III) was observed in only 2 of 8 patients (25%), both of whom experienced nausea/vomiting (grade III). With regard to late adverse reactions, brain necrosis (grade II) was observed in one patient. Three patients experienced ocular/visual problems (grade III to IV), but all of them were required orbital exenteration if surgery were indicated. Although ocular/visual problems were observed in patients with tumors invading the orbit, the primary disease was successfully controlled by RADPLAT in 7 of 8 patients. Therefore, RADPLAT is a sound option for T4 NC&ES.
Generally, in sinonasal malignancies, the prognosis is worse for SCCs than for adenocarcinomas. Further, primary tumors of the maxillary sinus have a better prognosis than those of the ethmoid sinus [12, 13] . Although there have been no reports focusing on Patients at risk Patients at risk Figure 3 
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